The Justice Department and the Department of Health and Human Services have opened a short, high-stakes window for healthcare companies that believe they may have overbilled federal health programmes. On October 22, 2026, the two departments launched a six-month Healthcare False Claims Act Self-Disclosure Pilot Program, under which a company that voluntarily discloses a potential civil violation previously unknown to the government can resolve it through a coordinated release from both departments, with no factual admissions and no Corporate Integrity Agreement, in exchange for a repayment calculated at 1.25 to 1.6 times a base amount. Disclosures must be submitted by April 22, 2027. Late or incomplete submissions will not be reviewed. For a company sitting on a billing problem, the pilot is a genuine opportunity, and also a genuine gamble: the same disclosure that buys a capped settlement also hands the government a detailed account of the conduct, and the pilot’s protections have sharp edges that advisers are already picking apart.
The pilot does not stand alone. A week earlier, on October 15, 2026, the Justice Department’s National Fraud Enforcement Division and the HHS Office of Inspector General announced a coordination policy for voluntary self-disclosure of potential criminal healthcare misconduct. Under that policy, one disclosure to the Fraud Division’s Health Care Fraud Section earns the benefits of both the department’s Corporate Enforcement Policy and the Inspector General’s Self-Disclosure Protocol, with the disclosure shared between the two bodies. The two October initiatives therefore create parallel tracks: a criminal track and a civil track, each with its own door, its own benefits, and its own risks. A company must decide, with advice, which door its facts belong behind, because the civil pilot is expressly for potential civil violations, while potential criminal conduct belongs on the criminal track. Choosing the wrong track, or disclosing only part of a problem, can forfeit the benefit the company hoped to buy.
How the DOJ HHS healthcare self-disclosure pilot works
The civil pilot is open to healthcare providers, suppliers, manufacturers, payors, and related entities that furnish, arrange for, manufacture, distribute, insure, administer, or bill for items or services reimbursed, subsidised, or otherwise paid for, directly or indirectly, by federal healthcare programmes. The participating HHS components are the Office of the General Counsel, the Office of Inspector General, and the Centers for Medicare and Medicaid Services. That breadth matters: a hospital system, a device maker, a pharmacy benefit manager, and a billing company can all, in principle, use the same door, provided the conduct fits the pilot’s conditions.
The central condition is that the disclosed conduct must involve a potential civil violation of the False Claims Act that was previously unknown to the federal government. If the government already knew about the conduct, the company cannot obtain a pilot resolution, although it may still seek self-disclosure and cooperation credit under the Justice Manual’s general provisions. The disclosure itself must be complete: the company must disclose all relevant details, provide documents showing the full nature and operation of the conduct, and describe the remedial steps it has taken. The pilot rejects partial submissions. That is a deliberate design choice, and it cuts both ways. It prevents a company from disclosing the smallest, safest slice of a problem while holding back the rest, but it also means a company that has not yet finished its own internal review faces a difficult choice between disclosing early and incompletely, which the pilot will not accept, and waiting to complete the review while the April 2027 deadline approaches.
The financial term is the pilot’s headline attraction. Under the False Claims Act as litigated, a company can face treble damages — three times the government’s loss — plus per-claim civil penalties. Under the pilot, repayment is calculated from a base self-disclosure amount, multiplied by 1.25 to 1.6. The exact multiplier turns on factors including the timeliness of the disclosure, the duration and scope of the misconduct, senior leadership involvement, the financial benefit the company obtained, and whether the company has successor liability but remediated promptly. A company that discloses quickly, for a short-lived problem, without senior involvement, should expect the lower end. A long-running problem that enriched the company and involved its leadership should expect the higher end. Even the higher end, however, is far below treble damages plus penalties, and that discount is the price the government is paying to persuade companies to come forward voluntarily rather than waiting to be caught.
In exchange, a qualifying company receives a coordinated civil release from the Justice Department for the disclosed potential violations, and HHS components agree not to impose certain administrative consequences as part of the resolution: the Inspector General will not impose an exclusion or require a Corporate Integrity Agreement, and Medicare and Medicaid will not revoke the provider’s or supplier’s enrolment and billing privileges. The departments’ joint announcement also states that neither CMS nor the Inspector General will impose civil monetary penalties as part of the resolution. That package — one disclosure, one repayment, one release, no compliance monitorship agreement — is what distinguishes the pilot from an ordinary negotiated settlement, where each agency might pursue its own remedy on its own timetable.
What the pilot does not resolve
The exclusions are as important as the benefits, and law firms analysing the protocol have flagged them carefully. The pilot does not expressly release claims against individuals, so executives and employees remain exposed even when the company settles. It does not resolve state claims, which matter because many healthcare fraud matters involve both federal and state Medicaid funds. It does not resolve pending qui tam actions — the whistleblower lawsuits filed under seal by private relators on the government’s behalf — and a company cannot use the pilot to extinguish a case a whistleblower has already filed. One analysis also notes that the protocol does not expressly release the Inspector General’s civil monetary penalty authorities in the same terms as the joint announcement’s summary, a tension that companies should clarify with counsel before relying on the broader reading. The safe way to describe the pilot, therefore, is that it resolves the disclosed federal civil False Claims Act liability and specified HHS administrative authorities, and leaves everything else to be assessed separately.
The relationship with the criminal track needs equal care. The pilot protocol does not indicate whether the Civil Division will refer matters to the National Fraud Enforcement Division, and the criminal coordination policy is a separate instrument with its own benefits under the Corporate Enforcement Policy. A company whose facts could support criminal charges should not assume that a civil pilot disclosure protects it criminally. Conversely, a company that discloses criminal conduct to the Fraud Division should not assume it has resolved its civil exposure. The two tracks are coordinated between agencies, but coordination is not the same as a single global release, and the departments have not promised one. Any company with mixed civil and criminal risk needs advice that spans both tracks before it files anything.
There are also practical traps. The pilot applies only to conduct implicating civil laws, so a company seeking the Corporate Enforcement Policy’s criminal benefits must disclose separately to the Fraud Division. The civil pilot requires a complete submission by a fixed deadline, while the criminal policy encourages early disclosure with rolling updates and the Inspector General’s protocol allows a period to complete a submitted disclosure. A company that starts on one timetable and drifts onto another can miss the pilot’s deadline or submit an incomplete filing that is simply not reviewed. The submission address published by the departments is a dedicated mailbox, and the deadline is 11:59 p.m. on April 22, 2027. That date is not a target; it is a cut-off.
Why the government is offering a discount
The departments’ stated rationale is resource allocation: by resolving past misconduct quickly through voluntary disclosure, the government can focus its enforcement resources on what its announcement calls “recalcitrant actors” — companies that do not come forward and must be investigated the hard way. There is also a deterrence logic. A capped, predictable settlement is worth more to a company than the threat of treble damages only if the company believes the alternative — detection, investigation, and litigation — is a real risk. Healthcare fraud enforcement has been a priority for years, with data analytics, whistleblower cases, and programme-integrity audits all increasing the odds that a billing pattern will be noticed. The pilot converts that background risk into a concrete choice with a deadline, which is a classic enforcement technique: make the voluntary path cheaper, make it time-limited, and let the company’s own risk assessment do the work.
Whether the pilot will attract many participants depends on how companies weigh three uncertainties. The first is scope: can a company be confident that what it discloses is the whole problem, given that billing systems, acquired subsidiaries, and legacy coding practices can hide additional issues? The second is the treatment of individuals and states, which the pilot leaves open and which can matter more to a board than the company’s own repayment. The third is the absence of precedent: because the pilot is new and runs for only six months, there is no track record of how the departments will apply the multiplier in practice, how strictly they will judge completeness, or how they will handle a disclosure that uncovers more than the company expected. Early participants will, in effect, test those questions for everyone else, and their experience — if it becomes public through later announcements — will shape whether the window is extended, repeated, or allowed to lapse.
For patients and taxpayers, the pilot’s value is indirect but real. Money recovered through self-disclosure returns to federal health programmes, and remediation steps required as part of disclosure — corrected billing, revised compliance controls, repaid claims — reduce the chance that the same pattern continues. The pilot does not, however, guarantee that any particular dollar is recovered, and it should not be described as an amnesty. A company that discloses pays a multiple of its base amount, accepts a release that is limited to the disclosed conduct, and remains subject to future enforcement for anything it did not disclose. The departments have offered a discount, not a pardon, and the difference matters for public understanding as much as for corporate strategy.
The window is now open, and the clock is the story. Companies with a known or suspected billing problem have until April 22, 2027, to decide whether the certainty of a capped civil resolution is worth the exposure of a complete disclosure. Companies that wait for a later, better offer may find that none comes. And companies that disclose without mapping the criminal, individual, state, and whistleblower dimensions of their facts may find that the pilot resolved less than they hoped. The pilot rewards preparation, and it punishes haste in equal measure — a combination that makes the next six months a revealing test of how American healthcare companies manage the problems they already know they have.
Healthcare fraud enforcement continues on other tracks as well, including recent federal action in Minnesota, where agents raided centres and charged defendants in a healthcare scheme (https://usnbreaking.com/minnesota-fraud-raids-fbi-charges-four-in-41-million-healthcare-scheme-after-st-cloud-crackdown/).
Sources
USN reviewed reporting from multiple outlets for this story. Read more from HHS (https://www.hhs.gov/press-room/hhs-doj-launch-healthcare-false-claims-act-self-disclosure-pilot.html), Holland & Knight (https://www.hklaw.com/en/insights/publications/2026/10/doj-and-hhs-launch-new-healthcare-false-claims-act) and JD Supra (https://www.jdsupra.com/legalnews/new-disclosure-pilot-program-doj-and-6224443/).